I don’t own shares in GlaxoSmithKline (LSE: GSK) or Unilever (LSE: ULVR), but my reasons for wanting to buy them have grown stronger. Actually, I do indirectly own a little of each through my holding in City of London Investment Trust, but both have now risen on my shortlist.
The two companies’ share prices moved strongly on Monday. At the time of writing, late morning, Glaxo shares are up 4% while Unilever is down 7%. But it’s not the movements that attract me. No, it’s the reason behind them.
Glaxo’s Consumer Healthcare division has never, in my view, fitted in with pharmaceuticals development. And that’s one of the things that’s held me back from buying in the past. I mean, what’s Sensodyne got to do with monoclonal antibody development? Or Eno with malaria vaccine research?
A consumer healthcare sell-off has long been in the pipeline, and Unilever has just made a bold move. The consumer products giant has offered £50bn to take the division off Glaxo’s hands. It’s apparently the third-largest takeover bid in UK stock market history, but commentators are already suggesting it could undervalue the target.
Glaxo was quick to reject the offer, saying that it “fundamentally undervalued the Consumer Healthcare business and its future prospects“. With the drugs firm reportedly valuing the division at £47bn-£48bn, Unilever did offer a pretty thin premium. But, as usual with such things, I’d say it’s likely there will be further offers. And I wonder if anyone else might want to get in on the act? It could get quite exciting if that were to happen.
Unmissable Unilever dip?
Why does the news make the two companies more attractive to me? Well, for one thing, there’s Unilever’s valuation. Sentiment seems to be against it right now, and the share price is down 16.5% over the past 12 months. Unilever’s 2021 first-half underlying earnings came in at €1.33 per share, compared to the €1.48 recorded for the full year in 2020.
To me, that suggests the 12-month fall in the Unilever share price is an anomaly, and I reckon it’s unjustified. I’ve always seen Unilever as one I’d like to buy on the dips. And the current dip is making it look like a good time for me to get in.
GlaxoSmithKline good value?
What about GlaxoSmithKline? a 20% rise in the past 12 months suggests there’s no dip to buy on here. But we’re still looking at a five-year gain of only a modest 10%. Glaxo shares are still well below their peak of January 2020. So GSK is also still on my candidates list. At the moment, though, Unilever is looking the better bargain to me.
Perhaps ironically, if I bought both Unilever and GlaxoSmithKline, and if the Consumer Healthcare bid is ultimately successful, I’d end up owning the same stuff. The only difference would be in who manages which parts. But Unilever in charge of consumer products makes a lot more sense to me.
5 Stocks For Trying To Build Wealth After 50
Markets around the world are reeling from the coronavirus pandemic…
And with so many great companies still trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.
But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.
Fortunately, The Motley Fool is here to help: our UK Chief Investment Officer and his analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global lock-down…
You see, here at The Motley Fool we don’t believe “over-trading” is the right path to financial freedom in retirement; instead, we advocate buying and holding (for AT LEAST three to five years) 15 or more quality companies, with shareholder-focused management teams at the helm.
That’s why we’re sharing the names of all five of these companies in a special investing report that you can download today for FREE. If you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio, and that you can consider building a position in all five right away.
Click here to claim your free copy of this special investing report now!
Alan Oscroft owns City of London Inv Trust. The Motley Fool UK has recommended GlaxoSmithKline and Unilever. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
